The invention relates to the chemical and pharmaceutical industry and medicine； more specifically, it relates to the methods of treatment of the acute cerebral and spinal circulation accidents. The treatment method consists in administering the pharmaceutical composition that contains the biologically active substance which substance is the protein-polypeptide complex and the pharmaceutically acceptable excipients which excipients contain the pharmaceutically acceptable diluent which diluent contains the officinal buffer solution, high molecular weight substances, stabilizers, preservatives, and solubilizers. The pharmaceutical composition is administered, 0.05 to 0.8 mg/day, subcutaneously, intramuscularly, intravenously, intranasally, and/or intrathecally.The protein-polypeptide complex, which is the biologically active substance (pharmacologic substance) of the pharmaceutical composition, is obtained from the mid first third to mid last third gestational age livestock embryonic brain tissue, which complex contains the negatively charged faintly acid, neutral proteins and polypeptides relating to the growth factor, differentiation factor, signaling molecules, and intercellular adhesion molecules, with the 5 to 200 kDa molecular masses, wherein at least 80% of the total protein mass has the 10 to 120 kDa molecular mass.
